Array Biopharma Inc., of Boulder, Colo., said interim results from an ongoing combination trial of ARRY-520 with Kyprolis (carfilozomib) in patients with relapsed or refractory multiple myeloma (MM) who are refractory or intolerant to Velcade (bortezomib) were reported at the European Hematology Association meeting.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter